{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:09:57Z","timestamp":1772752197598,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T00:00:00Z","timestamp":1546992000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1208\/s12248-018-0262-1","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T16:40:57Z","timestamp":1547052057000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Sorafenib N-Oxide Is an Inhibitor of Human Hepatic CYP3A4"],"prefix":"10.1208","volume":"21","author":[{"given":"Sussan","family":"Ghassabian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina B.","family":"Gillani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tristan","family":"Rawling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Severine","family":"Crettol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pramod C.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4233-7619","authenticated-orcid":false,"given":"Michael","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,9]]},"reference":[{"key":"262_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med. 2007;356:125\u201334. https:\/\/doi.org\/10.1056\/NEJMoa060655 .","journal-title":"New Engl J Med"},{"key":"262_CR2","doi-asserted-by":"publisher","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","volume":"66","author":"L Liu","year":"2006","unstructured":"Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5. Cancer Res. 2006;66:11851\u20138. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-1377 .","journal-title":"Cancer Res"},{"key":"262_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.ejca.2011.12.026","volume":"48","author":"A Awada","year":"2012","unstructured":"Awada A, Hendlisz A, Christensen O, Lathia CD, Bartholomeus S, Lebrun F, et al. Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours. Eur J Cancer. 2012;48:465\u201374. https:\/\/doi.org\/10.1016\/j.ejca.2011.12.026 .","journal-title":"Eur J Cancer"},{"key":"262_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s10637-012-9820-z","volume":"31","author":"N Azad","year":"2013","unstructured":"Azad N, Dasari A, Arcaroli J, Taylor GE, Laheru DA, Carducci MA, et al. Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. Investig New Drugs. 2013;31:345\u201354. https:\/\/doi.org\/10.1007\/s10637-012-9820-z .","journal-title":"Investig New Drugs"},{"key":"262_CR5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1634\/theoncologist.12-4-426","volume":"12","author":"D Strumberg","year":"2007","unstructured":"Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 2007;12:426\u201337. https:\/\/doi.org\/10.1634\/theoncologist.12-4-426 .","journal-title":"Oncologist"},{"key":"262_CR6","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1111\/j.1349-7006.2008.00837.x","volume":"99","author":"H Minami","year":"2008","unstructured":"Minami H, Kawada K, Ebi H, Kitagawa K, Kim YI, Araki K, et al. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci. 2008;99:1492\u20138. https:\/\/doi.org\/10.1111\/j.1349-7006.2008.00837.x .","journal-title":"Cancer Sci"},{"key":"262_CR7","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1200\/JCO.2011.34.7427","volume":"29","author":"H Inaba","year":"2011","unstructured":"Inaba H, Rubnitz JE, Coustan-Smith E, Li L, Furmanski BD, Mascara GP, et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed\/refractory leukemia. J Clin Oncol. 2011;29:3293\u2013300. https:\/\/doi.org\/10.1200\/JCO.2011.34.7427 .","journal-title":"J Clin Oncol"},{"key":"262_CR8","doi-asserted-by":"publisher","first-page":"e0167906","DOI":"10.1371\/journal.pone.0167906","volume":"11","author":"C Ferrario","year":"2016","unstructured":"Ferrario C, Strepponi I, Esfahani K, Charamis H, Langleben A, Scarpi E, et al. Phase I\/II trial of sorafenib in combination with vinorelbine as first-line chemotherapy for metastatic breast cancer. PLoS One. 2016;11:e0167906. https:\/\/doi.org\/10.1371\/journal.pone.0167906 .","journal-title":"PLoS One"},{"key":"262_CR9","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00280-005-0068-6","volume":"57","author":"C Lathia","year":"2006","unstructured":"Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol. 2006;57:685\u201392. https:\/\/doi.org\/10.1007\/s00280-005-0068-6 .","journal-title":"Cancer Chemother Pharmacol"},{"key":"262_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.bcp.2012.04.001","volume":"84","author":"S Ghassabian","year":"2012","unstructured":"Ghassabian S, Rawling T, Zhou F, Doddareddy MR, Tattam BN, Hibbs DE, et al. Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites. Biochem Pharmacol. 2012;84:215\u201323. https:\/\/doi.org\/10.1016\/j.bcp.2012.04.001 .","journal-title":"Biochem Pharmacol"},{"key":"262_CR11","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1093\/annonc\/mdl017","volume":"17","author":"H Richly","year":"2006","unstructured":"Richly H, Henning BF, Kupsch P, Passarge K, Grubert M, Hilger RA, et al. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol. 2006;17:866\u201373. https:\/\/doi.org\/10.1093\/annonc\/mdl017 .","journal-title":"Ann Oncol"},{"key":"262_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejca.2006.08.032","volume":"43","author":"K Mross","year":"2007","unstructured":"Mross K, Steinbild S, Baas F, Gmehling D, Radtke M, Voliotis D, et al. Results from an in vitro and a clinical\/pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer. 2007;43:55\u201363. https:\/\/doi.org\/10.1016\/j.ejca.2006.08.032 .","journal-title":"Eur J Cancer"},{"key":"262_CR13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1021\/tx500373g","volume":"28","author":"T Gillani","year":"2015","unstructured":"Gillani T, Rawling T, Murray M. Cytochrome P450-mediated biotransformation of sorafenib and its N-oxide metabolite: implications for cell viability and human toxicity. Chem Res Toxicol. 2015;28:92\u2013102. https:\/\/doi.org\/10.1021\/tx500373g .","journal-title":"Chem Res Toxicol"},{"key":"262_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1172\/JCI113299","volume":"81","author":"GC Farrell","year":"1988","unstructured":"Farrell GC, Koltai A, Murray M. The source of raised estrogens in male rats with portal bypass. J Clin Invest. 1988;81:221\u20138. https:\/\/doi.org\/10.1172\/JCI113299 .","journal-title":"J Clin Invest"},{"key":"262_CR15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/0960-0760(92)90248-H","volume":"43","author":"M Murray","year":"1992","unstructured":"Murray M. Participation of a cytochrome P450 enzyme from the 2C subfamily in progesterone 21-hydroxylation in sheep liver. J Steroid Biochem Mol Biol. 1992;43:591\u20133. https:\/\/doi.org\/10.1016\/0960-0760(92)90248-H .","journal-title":"J Steroid Biochem Mol Biol"},{"key":"262_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/FTD.0b013e318197e1bf","volume":"31","author":"S Ghassabian","year":"2009","unstructured":"Ghassabian S, Chetty M, Tattam BN, Glen J, Rahme J, Stankovic Z, et al. A high-throughput assay using liquid chromatography\/tandem mass spectrometry for simultaneous in vivo phenotyping of five major cytochrome P450 enzymes in patients. Ther Drug Monit. 2009;31:239\u201346. https:\/\/doi.org\/10.1097\/FTD.0b013e318197e1bf .","journal-title":"Ther Drug Monit"},{"key":"262_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/BF00562804","volume":"19","author":"MT Smith","year":"1981","unstructured":"Smith MT, Eadie MJ, Brophy TO. The pharmacokinetics of midazolam in man. Eur J Clin Pharmacol. 1981;19:271\u20138. https:\/\/doi.org\/10.1007\/BF00562804 .","journal-title":"Eur J Clin Pharmacol"},{"key":"262_CR18","doi-asserted-by":"publisher","first-page":"51S","DOI":"10.1111\/j.1365-2125.1983.tb02271.x","volume":"16","author":"C Crevoisier","year":"1983","unstructured":"Crevoisier C, Ziegler WH, Eckert M, Heizmann P. Relationship between plasma concentration and effect of midazolam after oral and intravenous administration. Br J Clin Pharmacol. 1983;16:51S\u201361S. https:\/\/doi.org\/10.1111\/j.1365-2125.1983.tb02271.x .","journal-title":"Br J Clin Pharmacol"},{"key":"262_CR19","first-page":"1278","volume":"268","author":"LL Moltke von","year":"1994","unstructured":"von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther. 1994;268:1278\u201383.","journal-title":"J Pharmacol Exp Ther"},{"key":"262_CR20","first-page":"931","volume":"42","author":"M Murray","year":"1992","unstructured":"Murray M. Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline. Mol Pharmacol. 1992;42:931\u20138.","journal-title":"Mol Pharmacol"},{"key":"262_CR21","doi-asserted-by":"publisher","first-page":"38091","DOI":"10.1074\/jbc.C400293200","volume":"279","author":"JK Yano","year":"2004","unstructured":"Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, Johnson EF. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-\u00c5 resolution. J Biol Chem. 2004;279:38091\u20134. https:\/\/doi.org\/10.1074\/jbc.C400293200 .","journal-title":"J Biol Chem"},{"key":"262_CR22","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1126\/science.1099736","volume":"305","author":"PA Williams","year":"2004","unstructured":"Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, et al. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science. 2004;305:683\u20136. https:\/\/doi.org\/10.1126\/science.1099736 .","journal-title":"Science"},{"key":"262_CR23","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1124\/dmd.110.037853","volume":"39","author":"M Sugiyama","year":"2011","unstructured":"Sugiyama M, Fujita K, Murayama N, Akiyama Y, Yamazaki H, Sasaki Y. Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1\u2032-hydroxylation. Drug Metab Dispos. 2011;39:757\u201362. https:\/\/doi.org\/10.1124\/dmd.110.037853 .","journal-title":"Drug Metab Dispos"},{"key":"262_CR24","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1016\/0040-4020(80)80168-2","volume":"36","author":"J Gasteiger","year":"1980","unstructured":"Gasteiger J, Marsili M. Iterative partial equalization of orbital electronegativity\u2014a rapid access to atomic charges. Tetrahedron. 1980;36:3219\u201328. https:\/\/doi.org\/10.1016\/0040-4020(80)80168-2 .","journal-title":"Tetrahedron"},{"key":"262_CR25","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/BF01593790","volume":"12","author":"MJD Powell","year":"1977","unstructured":"Powell MJD. Restart procedures for the conjugate gradient method. Math Program. 1977;12:241\u201354. https:\/\/doi.org\/10.1007\/BF01593790 .","journal-title":"Math Program"},{"key":"262_CR26","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/jcc.540100804","volume":"10","author":"M Clark","year":"1989","unstructured":"Clark M, Cramer RD III, Van Opdenbosch N. Validation of the general purpose tripos 5.2 force field. J Comput Chem. 1989;10:982\u20131012. https:\/\/doi.org\/10.1002\/jcc.540100804 .","journal-title":"J Comput Chem"},{"key":"262_CR27","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1021\/jm020406h","volume":"46","author":"AN Jain","year":"2003","unstructured":"Jain AN. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J Med Chem. 2003;46:499\u2013511. https:\/\/doi.org\/10.1021\/jm020406h .","journal-title":"J Med Chem"},{"key":"262_CR28","first-page":"940","volume":"24","author":"A Ghosal","year":"1996","unstructured":"Ghosal A, Satoh H, Thomas PE, Bush E, Moore D. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metab Dispos. 1996;24:940\u20137.","journal-title":"Drug Metab Dispos"},{"key":"262_CR29","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1124\/dmd.31.7.938","volume":"31","author":"KC Patki","year":"2003","unstructured":"Patki KC, Von Moltke LL, Greenblatt DJ. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: role of CYP3A4 and CYP3A5. Drug Metab Dispos. 2003;31:938\u201344. https:\/\/doi.org\/10.1124\/dmd.31.7.938 .","journal-title":"Drug Metab Dispos"},{"key":"262_CR30","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1074\/jbc.M111.317081","volume":"287","author":"IF Sevrioukova","year":"2012","unstructured":"Sevrioukova IF, Poulos TL. Structural and mechanistic insights into the interaction of cytochrome P4503A4 with bromoergocryptine, a type I ligand. J Biol Chem. 2012;287:3510\u20137. https:\/\/doi.org\/10.1074\/jbc.M111.317081 .","journal-title":"J Biol Chem"},{"key":"262_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2174\/138920007779315062","volume":"8","author":"C Graaf de","year":"2007","unstructured":"de Graaf C, Oostenbrink C, Keizers PH, van Vugt-Lussenburg BM, van Waterschoot RA, Tschirret-Guth RA, et al. Molecular modeling-guided site-directed mutagenesis of cytochrome P450 2D6. Curr Drug Metab. 2007;8:59\u201377. https:\/\/doi.org\/10.2174\/138920007779315062 .","journal-title":"Curr Drug Metab"},{"key":"262_CR32","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1021\/jm030489h","volume":"47","author":"P Ferrara","year":"2004","unstructured":"Ferrara P, Gohlke H, Price DJ, Klebe G, Brooks CL 3rd. Assessing scoring functions for protein-ligand interactions. J Med Chem. 2004;47:3032\u201347. https:\/\/doi.org\/10.1021\/jm030489h .","journal-title":"J Med Chem"},{"key":"262_CR33","doi-asserted-by":"publisher","first-page":"5856","DOI":"10.1021\/jm050040j","volume":"49","author":"TA Pham","year":"2006","unstructured":"Pham TA, Jain AN. Parameter estimation for scoring protein-ligand interactions using negative training data. J Med Chem. 2006;49:5856\u201368. https:\/\/doi.org\/10.1021\/jm050040j .","journal-title":"J Med Chem"},{"key":"262_CR34","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1007\/s11095-012-0724-6","volume":"29","author":"JR Kenny","year":"2012","unstructured":"Kenny JR, Mukadam S, Zhang C, Tay S, Collins C, Galetin A, et al. Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction. Pharm Res. 2012;29:1960\u201376. https:\/\/doi.org\/10.1007\/s11095-012-0724-6 .","journal-title":"Pharm Res"},{"key":"262_CR35","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1124\/dmd.114.057695","volume":"42","author":"AM Filppula","year":"2014","unstructured":"Filppula AM, Neuvonen PJ, Backman JT. In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014;42:1202\u20139. https:\/\/doi.org\/10.1124\/dmd.114.057695 .","journal-title":"Drug Metab Dispos"},{"key":"262_CR36","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s13318-016-0385-7","volume":"42","author":"P Giri","year":"2017","unstructured":"Giri P, Naidu S, Patel N, Patel H, Srinivas NR. Evaluation of in vitro cytochrome P450 inhibition and in vitro fate of structurally diverse N-oxide metabolites: case studies with clozapine, levofloxacin, roflumilast, voriconazole and zopiclone. Eur J Drug Metab Pharmacokinet. 2017;42:677\u201388. https:\/\/doi.org\/10.1007\/s13318-016-0385-7 .","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"262_CR37","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3109\/00498258509045370","volume":"15","author":"CB Marcus","year":"1985","unstructured":"Marcus CB, Murray M, Wilkinson CF. Spectral and inhibitory interactions of methylenedioxyphenyl and related compounds with purified isozymes of cytochrome P-450. Xenobiotica. 1985;15:351\u201362. https:\/\/doi.org\/10.3109\/00498258509045370 .","journal-title":"Xenobiotica"},{"key":"262_CR38","first-page":"902","volume":"43","author":"AM Butler","year":"1993","unstructured":"Butler AM, Murray M. Inhibition and inactivation of constitutive cytochromes P450 in rat liver by parathion. Mol Pharmacol. 1993;43:902\u20138.","journal-title":"Mol Pharmacol"},{"key":"262_CR39","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1146\/annurev.pa.23.040183.002405","volume":"23","author":"PR Ortiz de Montellano","year":"1983","unstructured":"Ortiz de Montellano PR, Correia MA. Suicidal destruction of cytochrome P-450 during oxidative drug metabolism. Annu Rev Pharmacol Toxicol. 1983;23:481\u2013503. https:\/\/doi.org\/10.1146\/annurev.pa.23.040183.002405 .","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"262_CR40","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1021\/tx970192k","volume":"11","author":"K He","year":"1998","unstructured":"He K, Iyer KR, Hayes RN, Sinz MW, Woolf T, Hollenberg PF. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol. 1998;11:252\u20139. https:\/\/doi.org\/10.1021\/tx970192k .","journal-title":"Chem Res Toxicol"},{"key":"262_CR41","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0278-6915(01)00060-6","volume":"39","author":"I Stupans","year":"2001","unstructured":"Stupans I, Murray M, Kirlich A, Tuck K, Hayball P. Inactivation of cytochrome P450 by the food-derived complex phenol oleuropein. Food Chem Toxicol. 2001;39:1119\u201324. https:\/\/doi.org\/10.1016\/S0278-6915(01)00060-6 .","journal-title":"Food Chem Toxicol"},{"key":"262_CR42","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/0003-9861(88)90202-0","volume":"262","author":"M Murray","year":"1988","unstructured":"Murray M. Complexation of cytochrome P-450 isoenzymes in hepatic microsomes from SKF 525-A-induced rats. Arch Biochem Biophys. 1988;262:381\u20138. https:\/\/doi.org\/10.1016\/0003-9861(88)90202-0 .","journal-title":"Arch Biochem Biophys"},{"key":"262_CR43","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/0006-2952(92)90163-D","volume":"43","author":"M Murray","year":"1992","unstructured":"Murray M, Field SL. Inhibition and metabolite complexation of rat hepatic microsomal cytochrome P450 by tricyclic antidepressants. Biochem Pharmacol. 1992;43:2065\u201371. https:\/\/doi.org\/10.1016\/0006-2952(92)90163-D .","journal-title":"Biochem Pharmacol"},{"key":"262_CR44","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1016\/0006-2952(84)90090-X","volume":"33","author":"M Murray","year":"1984","unstructured":"Murray M. In vitro effects of quinoline derivatives on cytochrome P-450 and aminopyrine N-demethylase activity in rat hepatic microsomes. Biochem Pharmacol. 1984;33:3277\u201381. https:\/\/doi.org\/10.1016\/0006-2952(84)90090-X .","journal-title":"Biochem Pharmacol"},{"key":"262_CR45","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1176\/ajp.153.3.311","volume":"153","author":"CB Nemeroff","year":"1996","unstructured":"Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatr. 1996;153:311\u201320. https:\/\/doi.org\/10.1176\/ajp.153.3.311 .","journal-title":"Am J Psychiatr"},{"key":"262_CR46","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1046\/j.1365-2125.2000.00134.x","volume":"49","author":"K Ohyama","year":"2000","unstructured":"Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T. Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol. 2000;49:244\u201353. https:\/\/doi.org\/10.1046\/j.1365-2125.2000.00134.x .","journal-title":"Br J Clin Pharmacol"},{"key":"262_CR47","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1200\/JCO.2008.20.0931","volume":"27","author":"AA Miller","year":"2009","unstructured":"Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G, et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol. 2009;27:1800\u20135. https:\/\/doi.org\/10.1200\/JCO.2008.20.0931 .","journal-title":"J Clin Oncol"},{"key":"262_CR48","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00280-011-1585-0","volume":"68","author":"KT Flaherty","year":"2011","unstructured":"Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, Rosen M, et al. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I\/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011;68:1111\u20138. https:\/\/doi.org\/10.1007\/s00280-011-1585-0 .","journal-title":"Cancer Chemother Pharmacol"},{"key":"262_CR49","doi-asserted-by":"publisher","first-page":"13682","DOI":"10.1073\/pnas.0603236103","volume":"103","author":"M Ekroos","year":"2006","unstructured":"Ekroos M, Sj\u00f6gren T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci U S A. 2006;103:13682\u20137. https:\/\/doi.org\/10.1073\/pnas.0603236103 .","journal-title":"Proc Natl Acad Sci U S A"},{"key":"262_CR50","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1016\/j.bbapap.2010.06.008","volume":"1804","author":"VH Teixeira","year":"2010","unstructured":"Teixeira VH, Ribeiro V, Martel PJ. Analysis of binding modes of ligands to multiple conformations of CYP3A4. Biochim Biophys Acta. 2010;1804:2036\u201345. https:\/\/doi.org\/10.1016\/j.bbapap.2010.06.008 .","journal-title":"Biochim Biophys Acta"},{"key":"262_CR51","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1021\/ci300118x","volume":"52","author":"U Bren","year":"2012","unstructured":"Bren U, Oostenbrink C. Cytochrome P450 3A4 inhibition by ketoconazole: tackling the problem of ligand cooperativity using molecular dynamics simulations and free-energy calculations. J Chem Inf Model. 2012;52:1573\u201382. https:\/\/doi.org\/10.1021\/ci300118x .","journal-title":"J Chem Inf Model"},{"key":"262_CR52","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1021\/tx5004062","volume":"27","author":"U Bren","year":"2014","unstructured":"Bren U, Fuchs JE, Oostenbrink C. Cooperative binding of aflatoxin B1 by cytochrome P450 3A4: a computational study. Chem Res Toxicol. 2014;27:2136\u201347. https:\/\/doi.org\/10.1021\/tx5004062 .","journal-title":"Chem Res Toxicol"},{"key":"262_CR53","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1080\/03602532.2016.1178771","volume":"48","author":"PC Nair","year":"2016","unstructured":"Nair PC, McKinnon RA, Miners JO. Cytochrome P450 structure-function: insights from molecular dynamics simulations. Drug Metab Rev. 2016;48:434\u201352. https:\/\/doi.org\/10.1080\/03602532.2016.1178771 .","journal-title":"Drug Metab Rev"},{"key":"262_CR54","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1073\/pnas.1616198114","volume":"114","author":"IF Sevrioukova","year":"2017","unstructured":"Sevrioukova IF, Poulos TL. Structural basis for regiospecific midazolam oxidation by human cytochrome P450 3A4. Proc Natl Acad Sci U S A. 2017;114:486\u201391. https:\/\/doi.org\/10.1073\/pnas.1616198114 .","journal-title":"Proc Natl Acad Sci U S A"},{"key":"262_CR55","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1124\/dmd.106.011304","volume":"35","author":"N Torimoto","year":"2007","unstructured":"Torimoto N, Ishii I, Toyama KI, Hata M, Tanaka K, Shimomura H, et al. Helices F-G are important for the substrate specificities of CYP3A7. Drug Metab Dispos. 2007;35:484\u201392. https:\/\/doi.org\/10.1124\/dmd.106.011304 .","journal-title":"Drug Metab Dispos"},{"key":"262_CR56","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1021\/acs.jmedchem.5b01146","volume":"59","author":"P Kaur","year":"2016","unstructured":"Kaur P, Chamberlin AR, Poulos TL, Sevrioukova IF. Structure-based inhibitor design for evaluation of a CYP3A4 pharmacophore model. J Med Chem. 2016;59:4210\u201320. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01146 .","journal-title":"J Med Chem"},{"key":"262_CR57","doi-asserted-by":"crossref","first-page":"9986","DOI":"10.1016\/S0021-9258(18)82162-7","volume":"268","author":"Y Seto","year":"1993","unstructured":"Seto Y, Guengerich FP. Partitioning between N-dealkylation and N-oxygenation in the oxidation of N,N-dialkylarylamines catalyzed by cytochrome P450 2B1. J Biol Chem. 1993;268:9986\u201397.","journal-title":"J Biol Chem"},{"key":"262_CR58","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1515\/DMDI.1998.14.4.221","volume":"14","author":"L Sk\u00e1lov\u00e1","year":"1998","unstructured":"Sk\u00e1lov\u00e1 L, Nobilis M, Szot\u00e1kov\u00e1 B, Ws\u00f3l V, Kvasnickov\u00e1 E. Induction and inhibition of cytochrome P450-catalysed reduction of biologically active benfluron N-oxide. Drug Metabol Drug Interact. 1998;14:221\u201333. https:\/\/doi.org\/10.1515\/DMDI.1998.14.4.221 .","journal-title":"Drug Metabol Drug Interact"},{"key":"262_CR59","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1021\/acs.molpharmaceut.7b00006","volume":"14","author":"JQ Ly","year":"2017","unstructured":"Ly JQ, Messick K, Qin A, Takahashi RH, Choo EF. Utility of CYP3A4 and PXR-CAR-CYP3A4\/3A7 transgenic mouse models to assess the magnitude of CYP3A4 mediated drug-drug interactions. Mol Pharm. 2017;14:1754\u20139. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00006 .","journal-title":"Mol Pharm"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-018-0262-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12248-018-0262-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-018-0262-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T00:26:16Z","timestamp":1662769576000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12248-018-0262-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,9]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["262"],"URL":"https:\/\/doi.org\/10.1208\/s12248-018-0262-1","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,9]]},"assertion":[{"value":"19 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Experiments in human liver microsomes were approved by ethics committees of the Western Sydney Area Health Service and the University of Sydney, according to the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}],"article-number":"15"}}